ArticlePloS one2025

Cost-effectiveness analysis of romosozumab for severe postmenopausal osteoporosis at very high risk of fracture in Mexico.

Juan Pablo Diaz Martinez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.